Pharma IQ

SEPTEMBER 5, 2024

Explore how digital transformation, particularly cloud technology and AI enhances efficiency and patient outcomes.

Healthcare 204

Healthcare Healthcare Patients 204

Fierce Pharma

SEPTEMBER 5, 2024

AstraZeneca has found its employees’ practices under the microscope of Chinese law enforcement years after an insurance fraud case. | AstraZeneca has found its employees’ practices under the microscope of Chinese law enforcement years after an insurance fraud case.

Insurance 363

Insurance Patients 363

pharmaphorum

SEPTEMBER 5, 2024

Listen to the podcast interview with Manny Belabe from ArisGlobal as he discusses The Life Sciences Generative AI Council and its role in creating a sustainable technological future. Gain insights into the future of AI in life sciences.

123

123

MedCity News

SEPTEMBER 4, 2024

Eli Lilly now offers vials of obesity medication Zepbound directly to self-pay patients at a nearly 50% discount off the drug’s list price. But more than offering patients a lower-cost alternative, this move represents a strategic stance against certain pharmaceutical industry players. The post With Direct-to-Patient Zepbound, Eli Lilly Takes a Stand Against Compounders and PBMs appeared first on MedCity News.

Patients 124

Patients Medical Pharmaceutical Biopharma 124

Advertisement

Pharmaceutical Commerce

SEPTEMBER 5, 2024

In the second part of her interview with Pharma Commerce Editor Nicholas Saraceno, Ilisa B.G. Bernstein, President of Bernstein Rx Solutions, LLC, discusses the best practices that compliance teams should consider as the end of the stabilization period approaches this November.

Pharma 105

Pharma 105

Fierce Pharma

SEPTEMBER 3, 2024

Late last year, Novo Nordisk responded to a growing shortage of popular Ozempic with a plan to cut down on production of its older diabetes med Victoza to make room for more Ozempic. | The company and the European Medicines Agency warned European healthcare providers to continue limiting new patient prescriptions until the shortages let up.

Healthcare Provider 315

Healthcare Provider Prescription Medicine Healthcare 315

MedCity News

SEPTEMBER 6, 2024

By 2030, the U.S. expects shortages of 200,000 nurses and 124,000 physicians snd similar shortages are already being felt in the U.K. and elsewhere. Here’s how to build and train a modern healthcare workforce in the age of AI The post Can AI Help Fix Our Demographic Time Bomb? appeared first on MedCity News.

Physicians 116

Physicians Training Healthcare Healthcare 116

Pharmaceutical Commerce

SEPTEMBER 3, 2024

In an interview with Pharma Commerce Editor Nicholas Saraceno, Ilisa B.G. Bernstein, President of Bernstein Rx Solutions, LLC, highlights the hard-hitting points that she anticipated will be covered during her session at the 2024 HDA Traceability Seminar.

Pharma 105

Pharma 105

Fierce Pharma

SEPTEMBER 5, 2024

Johnson & Johnson’s newly FDA-approved lung cancer combination of Rybrevant and Lazcluze is inching ever closer to a statistically significant survival showing, which could help it better chall | Johnson & Johnson’s newly FDA-approved lung cancer combination of Rybrevant and Lazcluze is inching ever closer to a statistically significant survival showing, which could help it better challenge AstraZeneca’s Tagrisso.

FDA 307

FDA 307

pharmaphorum

SEPTEMBER 5, 2024

A "small number" of AstraZeneca employees have been detained in China in an investigation into suspected data privacy and drug import breaches

114

114

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

MedCity News

SEPTEMBER 5, 2024

Cyril Philip, vice president of digital health ventures with Bon Secours Mercy Health and digital ventures lead for Accrete Health Partners, is taking part in a panel discussion at INVEST Digital Health in Dallas on September 18. In response to emailed questions, he addressed some of these challenges. The post What Challenges Do Implementing New Tech at a Hospital Pose?

Leads 115

Leads 115

Pharmaceutical Technology

SEPTEMBER 6, 2024

The US FDA has granted orphan drug designation (ODD) to Abdera Therapeutics’ ABD-147 aimed at neuroendocrine carcinoma.

FDA 124

FDA 124

Fierce Pharma

SEPTEMBER 6, 2024

GSK is heading into the weekend with a win for its respiratory blockbuster Nucala—but for now, the details are slim. | On Friday, GSK said that its IL-5 antibody Nucala plus inhaled maintenance therapy lowered the annualized rate of moderate or severe exacerbations among chronic obstructive pulmonary disease (COPD) patients for up to 2 years. Nucala is already approved in a range of respiratory conditions, but a COPD nod could present another big opportunity for the drug.

FDA 292

FDA Patients 292

pharmaphorum

SEPTEMBER 6, 2024

The fallout from the FDA's recent decision not to approve Lykos Therapeutics' psychedelic treatment has spread to its senior management, with chief executive Amy Emerson stepping down.

FDA 104

FDA Management 104

Advertiser: ZoomInfo

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

Competition

MedCity News

SEPTEMBER 5, 2024

Omada Health is a respected health tech company but what do customers see it? A flesh and blood and an AI analysis follows. The post What Do Consumers and AI Think Of Omada Health? appeared first on MedCity News.

115

115

Clarivate

SEPTEMBER 4, 2024

The Web of Science Research Assistant, a generative AI-powered tool built with and for researchers, is now available to the global research community. After extensive collaboration and testing with the research community that began in December 2023, we are pleased to announce the global launch of the Web of Science Research Assistant. The research assistant combines the power of generative artificial intelligence (AI), the Web of Science knowledge graph and an all-new chat interface to provide r

Government 98

Government Consulting Training Networking 98

Fierce Pharma

SEPTEMBER 4, 2024

Over the last decade, three blockbuster drugs—Biogen’s Spinraza, Roche’s Evrysdi and Novartis’ gene therapy Zolgensma—have transformed the treatment landscape for spinal muscular atrophy (SMA). | Biogen revealed that a portion of its phase 2/3 DEVOTE study met its primary endpoint, as a higher dose of Spinraza improved the motor function of treatment-naive infants with spinal muscular atrophy.

299

299

pharmaphorum

SEPTEMBER 1, 2024

Alnylam Pharma has been riding high since revealing top-line results from its HELIOS-B trial of vutrisiran in transthyretin-mediated amyloidosis (ATTR) – but a look at the full data seems to have disappointed investors.Shares in the company retreated after the presentation of the results at the European Society of Cardiology (ESC) conference, which confirmed a 28% reduction in the primary endpoint of deaths from any cause and recurrent cardiovascular events after at least 33 months of follow-up.

Pharma 110

Pharma 110

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

MedCity News

SEPTEMBER 6, 2024

The FDA decision for Travere Therapeutics’ Filspari also expands its addressable patient population. The full approval comes nearly a year after the Travere drug narrowly missed the main goal of its confirmatory study. The post Full FDA Approval of Travere’s Kidney Drug Stiffens Competition With Novartis, Calliditas appeared first on MedCity News.

Competition 113

Competition FDA Patients Biopharma 113

Pharmaceutical Technology

SEPTEMBER 4, 2024

By integrating the best practices from decentralized trials, CROs can optimize efficiencies and streamline site-based operations, ensuring that site-centric trials remain effective and innovative.

98

98

Fierce Pharma

SEPTEMBER 4, 2024

Several months after its parent company unveiled new labs and office space to unite cell and gene therapy research on the West Coast, Astellas Gene Therapies is turning out the lights at a Californ | Several months after its parent company unveiled new labs and office space to unite cell and gene therapy research on the West Coast, Astellas Gene Therapies is turning out the lights at a California production plant.

298

298

pharmaphorum

SEPTEMBER 4, 2024

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).The full results of the FENopta open-label extension study are due to be reported in full at the ECTRIMS congress in Copenhagen later this month, but top-line findings include that 99% of patients treated with fenebrutinib were free of T1 gadolinium-enhancing lesions, markers of active inflammation, at 48 w

Patients 104

Patients 104

Advertisement

Distribution

MedCity News

SEPTEMBER 4, 2024

In this episode, we’re joined by Carolee Lee, CEO and founder of Women’s Health Access Matters (WHAM), and Ash Shehata, KPMG U.S. sector leader for healthcare. The two discuss WHAM and KPMG’s new partnership that aims to advance women’s health research and investment. The post MedCity FemFwd: Inside WHAM & KPMG’s Women’s Health Partnership appeared first on MedCity News.

Healthcare 114

Healthcare Healthcare 114

Pharmaceutical Technology

SEPTEMBER 2, 2024

The US regulatory agency has also approved updated versions of Covid-19 vaccines from Moderna and Pfizer / BioNTech’s in the past two weeks.

FDA 105

FDA 105

Fierce Pharma

SEPTEMBER 5, 2024

With dwindling funds after a prior snub from the FDA, ImmunityBio’s journey to bag approval for its Merck-rivaling bladder cancer drug Anktiva wasn’t easy. | The drugmaker laid off 20 employees as it attempts to recoup from dwindling funds during its Anktiva launch in bladder cancer.

FDA 290

FDA 290

pharmaphorum

SEPTEMBER 3, 2024

EU had no grounds to probe Illumina's takeover of Grail, says ECJ, but while spinoff has already taken place Illumina can now avoid a €432m fine

114

114

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Safety

MedCity News

SEPTEMBER 5, 2024

Samsung announced its plans to acquire French medtech startup Sonio. The startup’s AI platform, which was cleared by the FDA last year, automates ultrasound reporting so that healthcare providers can conduct these exams with greater accuracy and efficiency. The post Samsung Acquires AI-Powered Prenatal Ultrasound Startup appeared first on MedCity News.

Healthcare Provider 114

Healthcare Provider Healthcare Healthcare FDA 114

Pharmaceutical Technology

SEPTEMBER 3, 2024

The UAE has partnered with Novo Nordisk Pharma Gulf to develop a national scientific guide for obesity management and weight control.

Management 107

Management Pharma 107

Fierce Pharma

SEPTEMBER 5, 2024

After handing over $30 million in criminal penalties last summer, Glenmark Pharmaceuticals has agreed to settle with the U.S. | Glenmark will pay the U.S. Department of Justice $25 million to resolve claims that it worked with other drugmakers to rig prices of the cholesterol med pravastatin. The case forms part of a larger antitrust probe implicating numerous manufacturers.

Manufacturing 285

Manufacturing Pharmaceutical 285

pharmaphorum

SEPTEMBER 5, 2024

Click Therapeutics' digital therapeutic for migraine clears late-stage study using an endpoint used to test drugs, clearing the way for regulatory filing.

FDA 107

FDA 107

Advertiser: ZoomInfo

In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.

Marketing